Industrial - Machinery
Compare Stocks
5 / 10Stock Comparison
IEX vs DHR vs EMR vs TMO vs HON
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Industrial - Machinery
Medical - Diagnostics & Research
Conglomerates
IEX vs DHR vs EMR vs TMO vs HON — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Industrial - Machinery | Medical - Diagnostics & Research | Industrial - Machinery | Medical - Diagnostics & Research | Conglomerates |
| Market Cap | $15.97B | $124.33B | $79.02B | $176.36B | $136.91B |
| Revenue (TTM) | $3.53B | $24.78B | $18.32B | $45.20B | $36.76B |
| Net Income (TTM) | $508M | $3.69B | $2.44B | $6.86B | $4.10B |
| Gross Margin | 44.4% | 60.7% | 52.7% | 39.4% | 36.9% |
| Operating Margin | 20.8% | 21.0% | 19.8% | 17.8% | 14.9% |
| Forward P/E | 25.5x | 20.8x | 21.7x | 19.1x | 20.5x |
| Total Debt | $1.82B | $18.42B | $13.76B | $40.85B | $34.58B |
| Cash & Equiv. | $580M | $4.62B | $1.54B | $9.86B | $12.49B |
IEX vs DHR vs EMR vs TMO vs HON — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| IDEX Corporation (IEX) | 100 | 134.8 | +34.8% |
| Danaher Corporation (DHR) | 100 | 118.9 | +18.9% |
| Emerson Electric Co. (EMR) | 100 | 231.2 | +131.2% |
| Thermo Fisher Scien… (TMO) | 100 | 135.9 | +35.9% |
| Honeywell Internati… (HON) | 100 | 148.1 | +48.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IEX vs DHR vs EMR vs TMO vs HON
Each card shows where this stock fits in a portfolio — not just who wins on paper.
IEX is the #2 pick in this set and the best alternative if growth exposure and valuation efficiency is your priority.
- Rev growth 5.8%, EPS growth -3.5%, 3Y rev CAGR 2.8%
- PEG 4.77 vs DHR's 34.35
- PEG 4.77 vs 11.18
- 7.3% ROA vs DHR's 4.5%, ROIC 10.4% vs 5.9%
DHR is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.94, Low D/E 35.1%, current ratio 1.87x
EMR ranks third and is worth considering specifically for momentum.
- +30.4% vs DHR's -8.3%
TMO is the clearest fit if your priority is long-term compounding.
- 229.1% 10Y total return vs EMR's 206.6%
- 15.2% margin vs HON's 11.2%
HON carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 15 yrs, beta 0.74, yield 2.1%
- Beta 0.74, yield 2.1%, current ratio 1.32x
- 7.8% revenue growth vs DHR's 2.9%
- Beta 0.74 vs EMR's 1.52
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.8% revenue growth vs DHR's 2.9% | |
| Value | PEG 4.77 vs 11.18 | |
| Quality / Margins | 15.2% margin vs HON's 11.2% | |
| Stability / Safety | Beta 0.74 vs EMR's 1.52 | |
| Dividends | 2.1% yield, 15-year raise streak, vs EMR's 1.5% | |
| Momentum (1Y) | +30.4% vs DHR's -8.3% | |
| Efficiency (ROA) | 7.3% ROA vs DHR's 4.5%, ROIC 10.4% vs 5.9% |
IEX vs DHR vs EMR vs TMO vs HON — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
IEX vs DHR vs EMR vs TMO vs HON — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
DHR leads in 1 of 6 categories
IEX leads 1 • EMR leads 1 • TMO leads 0 • HON leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
DHR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 12.8x IEX's $3.5B. Profitability is closely matched — net margins range from 15.2% (TMO) to 11.2% (HON). On growth, IEX holds the edge at +8.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3.5B | $24.8B | $18.3B | $45.2B | $36.8B |
| EBITDAEarnings before interest/tax | $945M | $7.2B | $4.7B | $10.5B | $6.5B |
| Net IncomeAfter-tax profit | $508M | $3.7B | $2.4B | $6.9B | $4.1B |
| Free Cash FlowCash after capex | $611M | $5.3B | $3.1B | $6.7B | $4.2B |
| Gross MarginGross profit ÷ Revenue | +44.4% | +60.7% | +52.7% | +39.4% | +36.9% |
| Operating MarginEBIT ÷ Revenue | +20.8% | +21.0% | +19.8% | +17.8% | +14.9% |
| Net MarginNet income ÷ Revenue | +14.4% | +14.9% | +13.3% | +15.2% | +11.2% |
| FCF MarginFCF ÷ Revenue | +17.3% | +21.4% | +17.0% | +14.9% | +11.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.9% | +3.7% | +2.9% | +6.2% | -6.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +27.8% | +9.8% | +28.2% | +11.3% | -41.9% |
Valuation Metrics
Evenly matched — DHR and TMO each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 26.8x trailing earnings, TMO trades at a 23% valuation discount to EMR's 34.9x P/E. Adjusting for growth (PEG ratio), IEX offers better value at 6.27x vs DHR's 34.35x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $16.0B | $124.3B | $79.0B | $176.4B | $136.9B |
| Enterprise ValueMkt cap + debt − cash | $17.2B | $138.1B | $91.2B | $207.4B | $159.0B |
| Trailing P/EPrice ÷ TTM EPS | 33.51x | 34.85x | 34.92x | 26.75x | 29.36x |
| Forward P/EPrice ÷ next-FY EPS est. | 25.52x | 20.82x | 21.71x | 19.11x | 20.52x |
| PEG RatioP/E ÷ EPS growth rate | 6.27x | 34.35x | 7.73x | 12.67x | 15.99x |
| EV / EBITDAEnterprise value multiple | 18.58x | 18.21x | 18.07x | 19.04x | 19.99x |
| Price / SalesMarket cap ÷ Revenue | 4.62x | 5.06x | 4.39x | 3.96x | 3.66x |
| Price / BookPrice ÷ Book value/share | 4.02x | 2.38x | 3.94x | 3.34x | 9.00x |
| Price / FCFMarket cap ÷ FCF | 25.89x | 23.64x | 29.63x | 28.02x | 25.39x |
Profitability & Efficiency
IEX leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
HON delivers a 23.1% return on equity — every $100 of shareholder capital generates $23 in annual profit, vs $7 for DHR. DHR carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to HON's 2.24x. On the Piotroski fundamental quality scale (0–9), IEX scores 7/9 vs HON's 6/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +12.6% | +7.1% | +12.1% | +13.2% | +23.1% |
| ROA (TTM)Return on assets | +7.3% | +4.5% | +5.8% | +6.4% | +5.3% |
| ROICReturn on invested capital | +10.4% | +5.9% | +8.2% | +7.5% | +12.6% |
| ROCEReturn on capital employed | +11.6% | +7.0% | +10.0% | +9.1% | +12.6% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 7 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.45x | 0.35x | 0.68x | 0.76x | 2.24x |
| Net DebtTotal debt minus cash | $1.2B | $13.8B | $12.2B | $31.0B | $22.1B |
| Cash & Equiv.Liquid assets | $580M | $4.6B | $1.5B | $9.9B | $12.5B |
| Total DebtShort + long-term debt | $1.8B | $18.4B | $13.8B | $40.9B | $34.6B |
| Interest CoverageEBIT ÷ Interest expense | 11.33x | 18.13x | 6.46x | 5.89x | 3.92x |
Total Returns (Dividends Reinvested)
EMR leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in EMR five years ago would be worth $15,945 today (with dividends reinvested), compared to $7,893 for DHR. Over the past 12 months, EMR leads with a +30.4% total return vs DHR's -8.3%. The 3-year compound annual growth rate (CAGR) favors EMR at 20.7% vs DHR's -5.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +20.4% | -23.6% | +4.3% | -19.8% | +10.9% |
| 1-Year ReturnPast 12 months | +20.9% | -8.3% | +30.4% | +16.8% | +2.8% |
| 3-Year ReturnCumulative with dividends | +5.9% | -15.5% | +75.9% | -11.7% | +16.2% |
| 5-Year ReturnCumulative with dividends | +0.7% | -21.1% | +59.5% | +2.8% | +3.3% |
| 10-Year ReturnCumulative with dividends | +189.3% | +219.3% | +206.6% | +229.1% | +135.1% |
| CAGR (3Y)Annualised 3-year return | +1.9% | -5.5% | +20.7% | -4.0% | +5.1% |
Risk & Volatility
Evenly matched — IEX and HON each lead in 1 of 2 comparable metrics.
Risk & Volatility
HON is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than EMR's 1.52 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IEX currently trades 96.0% from its 52-week high vs DHR's 72.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.95x | 0.94x | 1.52x | 1.10x | 0.74x |
| 52-Week HighHighest price in past year | $223.84 | $242.80 | $165.15 | $643.99 | $248.18 |
| 52-Week LowLowest price in past year | $157.25 | $172.06 | $108.37 | $385.46 | $186.76 |
| % of 52W HighCurrent price vs 52-week peak | +96.0% | +72.3% | +85.4% | +73.7% | +87.1% |
| RSI (14)Momentum oscillator 0–100 | 67.6 | 33.0 | 61.3 | 43.1 | 45.1 |
| Avg Volume (50D)Average daily shares traded | 713K | 4.2M | 2.8M | 1.9M | 3.7M |
Analyst Outlook
Evenly matched — EMR and HON each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: IEX as "Hold", DHR as "Buy", EMR as "Buy", TMO as "Buy", HON as "Buy". Consensus price targets imply 40.6% upside for DHR (target: $247) vs 12.7% for IEX (target: $242). For income investors, HON offers the higher dividend yield at 2.14% vs TMO's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $242.14 | $247.00 | $161.92 | $654.67 | $243.83 |
| # AnalystsCovering analysts | 29 | 42 | 41 | 42 | 28 |
| Dividend YieldAnnual dividend ÷ price | +1.3% | +0.7% | +1.5% | +0.4% | +2.1% |
| Dividend StreakConsecutive years of raises | 23 | 1 | 37 | 8 | 15 |
| Dividend / ShareAnnual DPS | $2.82 | $1.23 | $2.10 | $1.69 | $4.63 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.6% | +2.5% | +1.6% | +1.7% | +2.8% |
DHR leads in 1 of 6 categories (Income & Cash Flow). IEX leads in 1 (Profitability & Efficiency). 3 tied.
IEX vs DHR vs EMR vs TMO vs HON: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is IEX or DHR or EMR or TMO or HON a better buy right now?
For growth investors, Honeywell International Inc.
(HON) is the stronger pick with 7. 8% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 8x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Danaher Corporation (DHR) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — IEX or DHR or EMR or TMO or HON?
On trailing P/E, Thermo Fisher Scientific Inc.
(TMO) is the cheapest at 26. 8x versus Emerson Electric Co. at 34. 9x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IDEX Corporation wins at 4. 77x versus Danaher Corporation's 34. 35x.
03Which is the better long-term investment — IEX or DHR or EMR or TMO or HON?
Over the past 5 years, Emerson Electric Co.
(EMR) delivered a total return of +59. 5%, compared to -21. 1% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: TMO returned +229. 1% versus HON's +135. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — IEX or DHR or EMR or TMO or HON?
By beta (market sensitivity over 5 years), Honeywell International Inc.
(HON) is the lower-risk stock at 0. 74β versus Emerson Electric Co. 's 1. 52β — meaning EMR is approximately 105% more volatile than HON relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 2% for Honeywell International Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — IEX or DHR or EMR or TMO or HON?
By revenue growth (latest reported year), Honeywell International Inc.
(HON) is pulling ahead at 7. 8% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: Emerson Electric Co. grew EPS 17. 8% year-over-year, compared to -15. 5% for Honeywell International Inc.. Over a 3-year CAGR, EMR leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — IEX or DHR or EMR or TMO or HON?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus 12. 6% for Honeywell International Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DHR leads at 20. 9% versus 17. 5% for HON. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is IEX or DHR or EMR or TMO or HON more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, IDEX Corporation (IEX) is the more undervalued stock at a PEG of 4. 77x versus Danaher Corporation's 34. 35x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 1x forward P/E versus 25. 5x for IDEX Corporation — 6. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 40. 6% to $247. 00.
08Which pays a better dividend — IEX or DHR or EMR or TMO or HON?
All stocks in this comparison pay dividends.
Honeywell International Inc. (HON) offers the highest yield at 2. 1%, versus 0. 4% for Thermo Fisher Scientific Inc. (TMO).
09Is IEX or DHR or EMR or TMO or HON better for a retirement portfolio?
For long-horizon retirement investors, Honeywell International Inc.
(HON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74), 2. 1% yield, +135. 1% 10Y return). Both have compounded well over 10 years (HON: +135. 1%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between IEX and DHR and EMR and TMO and HON?
These companies operate in different sectors (IEX (Industrials) and DHR (Healthcare) and EMR (Industrials) and TMO (Healthcare) and HON (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
IEX, DHR, EMR, HON pay a dividend while TMO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.